Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases.

Details

Ressource 1Download: cancers-14-02557.pdf (582.29 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_EF517F1A0E38
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases.
Journal
Cancers
Author(s)
Balmer A., Clerc D., Toussaint L., Sgarbura O., Taïbi A., Hübner M., Teixeira Farinha H.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
23/05/2022
Peer-reviewed
Oui
Volume
14
Number
10
Pages
2557
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
The standard treatment protocol for PIPAC consists of three procedures. Completion of treatment has been shown to be prognostic of improved survival. The aim of this study was to identify predictors for completion of treatment.
Retrospective multicentric cohort study of patients with peritoneal metastases undergoing PIPAC in three PIPAC expert centers. Per protocol (PP) treatment was defined as patients receiving ≥3 PIPACs and was compared to patients receiving <3.
Overall, 183 patients had 517 PIPACs. The main reasons for stopping PIPAC were disease progression in 50% patients, bowel obstruction in 15%, patient's refusal to pursue in 10%, conversion to cytoreductive surgery in 7%, and medical reasons in 8%. Overall, 95 patients (52%) had PP treatment. The PP median OS was 17 vs. 7 months, p = 0.001. PP patients had r ascites (410 ± 100 mL vs. 960 ± 188 mL, p = 0.001), no prior history of bowel obstruction (12% vs. 24%, p = 0.028), and more bimodal treatment (39% vs. 13%, p < 0.001). After multiple regression, bimodal treatment was found as an independent predictive factor for completing PP (OR = 4.202, 95%CI [1.813, 10.630], p < 0.001), along with prior bowel obstruction (OR = 0.389, 95%CI [0.153, 0.920], p = 0.037).
The absence of ascites and prior bowel obstruction can help to select patients suitable for PIPAC. Best results seem to be achieved when PIPAC is combined with systemic chemotherapy.
Keywords
Cancer Research, Oncology, PIPAC, carcinomatosis, peritoneal cancer, peritoneal metastases, peritoneal surface malignancies
Pubmed
Web of science
Open Access
Yes
Create date
25/05/2022 9:18
Last modification date
18/06/2022 6:34
Usage data